Norinchukin Bank The buys $27,929,065 stake in Pfizer (PFE)

Pfizer (PFE) : Norinchukin Bank The scooped up 6,996 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 794,568 shares of Pfizer which is valued at $27,929,065.Pfizer makes up approximately 0.65% of Norinchukin Bank The’s portfolio.

Other Hedge Funds, Including , Suffolk Capital Management sold out all of its stake in PFE during the most recent quarter. The investment firm sold 319,334 shares of PFE which is valued $11,224,590.State Board Of Administration Of Florida Retirement System boosted its stake in PFE in the latest quarter, The investment management firm added 1,353,298 additional shares and now holds a total of 8,971,982 shares of Pfizer which is valued at $317,967,042. Pfizer makes up approx 0.97% of State Board Of Administration Of Florida Retirement System’s portfolio.First Quadrant L Pca reduced its stake in PFE by selling 1,105,700 shares or 69.34% in the most recent quarter. The Hedge Fund company now holds 488,836 shares of PFE which is valued at $17,930,504. Pfizer makes up approx 0.38% of First Quadrant L Pca’s portfolio.Gradient Investments boosted its stake in PFE in the latest quarter, The investment management firm added 12,206 additional shares and now holds a total of 129,601 shares of Pfizer which is valued at $4,748,581. Pfizer makes up approx 0.51% of Gradient Investments’s portfolio.

Pfizer opened for trading at $35.05 and hit $35.17 on the upside on Monday, eventually ending the session at $35.11, with a gain of 0.37% or 0.13 points. The heightened volatility saw the trading volume jump to 1,23,54,034 shares. Company has a market cap of $212,965 M.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.